Norman joined the HTX team in April 2008 where he serves as the Director of Business Development and Investment.
Norman brings to the team an extensive background in life sciences, corporate finance, and entrepreneurship with leadership roles within emerging life sciences and technology start-ups. As the former Life Sciences Analyst at Octagon Capital and former Healthcare investment banker with Yorkton Securities, Norman worked on numerous public and private equity transactions within the health sciences sector. At Cannasat Therapeutics (CTH: TSXV), Norman managed and executed strategic initiatives across all functions of the corporation and played an integral role in raising capital, including Cannasat’s ”going public” transaction. Most recently, Norman was the Chief Financial Officer and Director of BroadShift Inc, an emerging technology and media start-up on the path towards an IPO.
Norman earned his MBA from the Richard Ivey School of Business in 2001, his MSc in Pharmacology from the University of Toronto in 1996, and a BSc (Honours) in Life Sciences from Queen’s University in 1993.
